Development of polymeric nanocarrier systems and in vitro studies

Ismayılova N., Sakarya D., Kalaycılar İ. B., Barlas F. B., Yücel S., İnce E.

5th International Eurasian Conference on Biological and Chemical Sciences (EurasianBioChem 2022) November 23-25, 2022, Ankara, Türkiye, 23 - 25 Kasım 2022, ss.159, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Ankara
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.159
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Lung cancer remains the leading cause of cancer-related deaths in men and women (1). The distribution by level of economic development shows that there is no difference in cancer deaths among men, but lung cancer deaths are higher in industrialized countries than in developing countries. In addition, lung cancer deaths among women in developing countries lag behind breast cancer-related deaths (2). This study aims to encapsulate Doxorubicin into PCL nanoparticles and to investigate the efficacy of these Nano formulations on A549 lung cell line in vitro. PCL (FDA-approved), has been used as a drug delivery system in the development of targeted drugs against cancer in recent years and shows biocompatible, biodegradable properties. The carrier systems were synthesized with 14.000 kDa Polycaprolactone (PCL) according to the Nanoprecipitation method and 1 mg/mL doxorubicin (Dox) was encapsulated by the Double emulsion method. Encapsulation efficiency was evaluated by Ultraviolet-Visible spectroscopy (UV-VIS), Dimensional Analysis Dynamic Light Scattering (DLS) and Scanning Electron Microscopy (SEM), and dialysis membranes at two different pH (6 and 7.4) were used for drug release studies. The particle size of the prepared DOX-PCL is in the range of 200-220 nm. The results of the multidispersion index study showed that the nanoformulations had a monodisperse structure and the PDI value was less than 0.3. Cytotoxicity analyses (MTT) and fluorescence imaging studies were performed to observe the effects on living systems. According to cell culture studies, it was determined that POL-DOX decreased the viability on the A549 cell line more than free DOX and accumulated in the cell nucleus. As a result, it has been observed that POLDOX has a high potential to be an effective formulation in the chemical treatment of cancer, and also has a theranostic structure that allows systems that can allow secondary treatments such as photodynamic therapy and radiotherapy.